These findings suggest that while heart failure may lead to modest increases in systemic exposure of certain SGLT2 inhibitors, these changes remain within a therapeutically acceptable range and do not necessitate dose adjustment for dapagliflozin or empagliflozin. This evidence concerns the gene SLC5A2 and heart failure.